A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Aptamers, Nucleotide
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Oligodeoxyribonucleotides
  • Phosphoproteins
  • RNA-Binding Proteins

abstract

  • AS1411 appears to have minimal activity in unselected patients with metastatic RCC. However, rare, dramatic and durable responses can be observed and toxicity is low. One patient in this study had an excellent response and was found to have FGFR2 and mTOR mutations which will be of interest in future efforts to discover and validate predictive biomarkers of response to nucleolin targeted compounds. DNA aptamers represent a novel way to target cancer cells at a molecular level and continue to be developed with a view to improving treatment and imaging in cancer medicine.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4560460

Digital Object Identifier (DOI)

  • 10.1007/s10637-013-0045-6

PubMed ID

  • 24242861

Additional Document Info

start page

  • 178

end page

  • 87

volume

  • 32

number

  • 1